PDF
ePub
Citation
Print
Abstract
Depression is a heterogeneous group of syndromes comprised of numerous diseases of distinct causes and pathophysiologies. Recently, several promising hypotheses of depression and antidepressant action have been formulated. These hypotheses are largely based on dysregulation of neural plasticity, CREB, BDNF, corticotropin-releasing factor, glucocorticoid, hypothalamicpituitary adrenal axis and cytokines. Recent work has revealed that several brain regions such as hippocampus, prefrontal cortex, amygdala, nucleus accumbens, and other hypothalamic nuclei are involved in the neural circuit of depression. The brain regions are critical in regulating memory, mood, motivation, sleep, eating, circadian rhythm and responses to rewarding and adverse stimuli, which are all abnormal in depressed patients. The neurobiological understanding of depression will fundamentally improve the treatment and prevention of that illness.
References
1. Schildkraut JJ. The catecholamine hypothesis of affective disorders : a review of supporting evidence. Am J Psychiatry. 1965. 122(5):509–522.
2. Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. Arch Gen Psychiatry. 1981. 38(10):1160–1180.
3. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci. 1994. 15(7):220–226.
4. Blier P, Pineyro G, el Mansari M, Bergeron R, de Montigny C. Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann N Y Acad Sci. 1998. 861:204–216.
5. Zanardi R, Artigas F, Franchini L, Sforzini L, Gasperini M, Smeraldi E, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol. 1997. 17(6):446–450.
6. Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F. Grup de Recerca en Trastorns Afectius. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry. 1999. 56(4):375–379.
7. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997. 54(7):597–606.
8. Kim YK. The new neurobiology of depression. Journal of Korean Society of Biological Psychiatry. 2001. 8(1):3–19.
9. Heim C, Nemeroff CB. The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders. Biol Psychiatry. 1999. 46(11):1509–1522.
10. Kaufman J, Plotsky PM, Nemeroff CB, Charney DS. Effects of early adverse experiences on brain structure and function : clinical implications. Biol Psychiatry. 2000. 48(8):778–790.
11. Steckler T, Holsboer F. Corticotropin-releasing hormone receptor subtypes and emotion. Biol Psychiatry. 1999. 46(11):1480–1508.
12. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 1999. 160(1):1–12.
13. kim YK, Choi SH, kim JY, Kim DH, Lee KJ, Shin KH. Effects of repeated stress on expression of corticotropin releasing factor type I and II receptors. J Korean Neuropsychiatr Assoc. 2003. 42(4):445–453.
14. Holsboer F. The rationale for corticotropin-releasing hormone receptor(CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res. 1999. 33(3):181–214.
15. Gold PW, Drevets WC, Charney DS. New insights into the role of cortisol and the glucocorticoid receptor in severe depression. Biol Psychiatry. 2002. 52(5):381–385.
16. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci. 1999. 19(12):5034–5043.
17. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 2000. 23(5):477–501.
18. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol. 2001. 21:516–521.
19. Rothermundt M, Arolt V, Peters M, Gutbrodt H, Fenker J, Kersting A, et al. Inflammatory markers in major depression and melancholia. J Affect Disord. 2001. 63(1-3):93–102.
20. Kronfol Z, Remick DG. Cytokines and the brain:implications for clinical psychiatry. Am J Psychiatry. 2000. 157(5):683–694.
21. Maes M, Smith R, Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology. 1995. 20(2):111–116.
22. Kim YK, Suh IB, Kim H, Han CS, Lim CS, Choi SH, et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania:effects of psychotropic drugs. Mol Psychiatry. 2002. 7(10):1107–1114.
23. Leonard BE. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2001. 25(4):767–780.
24. Kim YK, Maes M. The role of cytokine network in psychological stress. Acta Neuropsychiatrica. 2003. 15:148–155.
25. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res. 1994. 643(1-2):40–49.
26. Ramamoorthy S, Ramamoorthy JD, Prasad PD, Bhat GK, Mahesh VB, Leibach FH, et al. Regulation of the human serotonin transporter by interleukin-1 beta. Biochem Biophys Res Commun. 1995. 216(2):560–567.
27. Myint AM, Kim YK. Cytokine-serotonin interaction through IDO : A neurodegeneration hypothesis of depression. Med Hypotheses. 2003. (in press).
28. Kim YK. The role of cytokines in depression and their therapeutic implication. Korean J Psychopharmacol. 2000. 11(4):304–312.
29. Sheline YI. 3D MRI studies of neuroanatomic changes in unipolar major depression:the role of stress and medical comorbidity. Biol Psychiatry. 2000. 48(8):791–800.
30. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry. 2000. 48(8):813–829.
31. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron. 2002. 34(1):13–25.
32. Duman RS. Synaptic plasticity and mood disorders. Mol Psychiatry. 2002. 7:Suppl 1. S29–S34.
33. Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, Duman RS. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J Neurosci. 1999. 19(2):610–618.
34. Farvolden P, Kennedy SH, Lam RW. Recent developments in the psychobiology and pharmacotherapy of depression : optimising existing treatments and novel approaches for the future. Expert Opin Investig Drugs. 2003. 12(1):65–86.
XML Download